We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective.
- Authors
Garside, Ruth; Pitt, Martin; Anderson, Rob; Mealing, Stuart; D'Souza, Richard; Stein, Ken
- Abstract
Secondary hyperparathyroidism (SHPT) is a common side effect of end-stage renal disease (ESRD) and is associated with increased risk of fracture and cardiovascular events (CV). Current standard treatment includes dietary control, phosphate binders and vitamin D. However, many patients do not have their parathyroid hormone (PTH), calcium and phosphate levels controlled by this regimen. Cinacalcet is the first of a new class of calcimimetic drugs which suppress PTH production. Although there is convincing evidence of the impact of cinacalcet on serum biomarkers, the long-term clinical implications of treatment are less clear. The aim of this study is to estimate the cost-utility of cinacalcet as an addition to standard treatment of SHPT compared with standard treatment alone.
- Publication
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Vol 22, Issue 5, p1428
- ISSN
0931-0509
- Publication type
Journal Article
- DOI
10.1093/ndt/gfl774